Prakt. lékáren. 2012; 8(4): 177-180
Pharmaceutical care in patiens with benign prostate hyperplasia
- Katedra sociální a klinické farmacie, Farmaceutická fakulta UK Hradec Králové
- II. interní klinika, Fakultní nemocnice Hradec Králové
Prostate gland represents an auxiliary male gonadal gland. The hormone-induced growth of prostate gland is responsible for characteristic
disturbances in urination at advanced age. Clinically, we term it LUTS/BHP or symptoms of lower urinary tract based on benign
prostate hyperplasia. Incidence and prevalence of this disease increase with age. Therapy is preferentially aimed at the maintenance of
the quality of life of patients with choice of monitoring, use of pharmacologically active compounds or surgical intervention. Pharmacotherapy
of benign prostate hyperplasia uses phytopharmaceuticals, alphablockers and 5-alpha reductase blockers. Pharmaceutical care
finds its use during diagnostics of this disease, in particular while providing an analysis of patient´s problems, consultation concerning
symptomatic treatment and a complete information service during dispensation.
Keywords: prostate gland, LUTS/BHP, phytopharmaceuticals, alphablockers, 5-alpha reductase blockers, pharmaceutical care
Published: July 31, 2012 Show citation
References
- Ganong WF. Přehled lékařské fyziologie. Praha: Galén, 2005: 890.
- Kotlář M. Fytopreparáty v léčbě a prevenci onemocnění prostaty. Tempus med 2011; 1: 22-25.
- http://commons.wikimedia.org/wiki/File:Benign_Prostatic_Hyperplasia_nci-vol-7137-300.jpg) [navštíveno 16.04.2012].
- Broďák M, Holub L. Farmakoterapie benigní hyperplazie prostaty - prevence, účinné preparáty, nežádoucí účinky. Urolog. pro Praxi 2006; 5: 210-213.
- Jabor A, Hornová L, Fantová L, Engliš M. Vyšetření funkce ledvin: možnosti biochemické laboratoře. Postgrad Med 2006; 1: 18-22.
- Ulbricht C, Seamon E. Natural Standard Herbal Pharmacotherapy. An Evidence-Based Approach. Canada: Mosby, 2009: 648.
Go to original source... - Madersbacher S, Alivizatos G, Nordling J, et al. EAU 2004 Guidelines on Assessment, Therapy and Follow-Up of Men with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Obstruction (BPH Guidelines). Eur Urol 2004; 46: 547-554. Go to original source...
Go to PubMed... - Cancer Facts: Chemoprevention. Bethseda, MD: National Cancer Institute 2002.
- Tavani A, Longoni E, Bosetti C, et al. Intake of selected micronutrients and the risk of surgically treated benign prostatic hyperplasia: a case-control study from Italy. Eur Urol 2006; 50: 549-554. Go to original source... Go to PubMed...
- Hora M. Fytopreparáty v léčbě BHP. Urol Listy 2004; 4: 42-45.
- Chapple C, Batista JE, Berges R, et al. The impact of nocturia in patients with LUTS/BHP: Need for new recommendations. EurUrol 2006; 5(1): 12-18. Go to original source...
- Djavan B, Marberger M. A meta-analysis on the efficacy and tolerability of alpha 1-adrenoreceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Eur Urol 1999; 36: 1-13. Go to original source... Go to PubMed...
- Marberger M, Harkaway R, de la Rosette J. Optimizing the medical management of benign prostatic hyperplasia. Eur Urol 2004; 45: 411-419. Go to original source... Go to PubMed...
- MacDonald JD, Roehrborn CG, Bautista OM, et al. Afluzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia" a systematic review of efficacy and adverse effects. Urology 2005; 66(4): 780-788. Go to original source... Go to PubMed...
- Debruyne F, Barkin J, van Erps P, et al. Efficacy and safety of long-term treatment with dual 5 alpha- reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 2004; 46: 488-495. Go to original source... Go to PubMed...
- Cohen SA, Parsons JK. Combination pharmacological therapies for the management of benign prostatic hyperplasia. Drugs Aging 2012; 29(4): 275-284. Go to original source... Go to PubMed...
- Gacci M, Corona G, Salvi M, Vignozzi L, McVary KT, Kaplan SA, Roehrborn CG, Serni S, Mirone V, Carini M, Maggi M. A Systematic Review and Meta-analysis on the Use of Phosphodiesterase 5 Inhibitors Alone or in Combination with ?-Blockers for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia. Eur Urol 2012; 61(5): 994-1003. Epub 2012 Feb 25. Go to original source... Go to PubMed...